Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01643603 · ClinicalTrials.gov registry record · Phase 1
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
A Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01643603 is a Phase 1 study that was terminated before completion, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 5 participants.
The verdict
NCT01643603, a Phase 1 study, was terminated before completion, sponsored by Barbara Ann Karmanos Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells. Researchers think that dasatinib may cause large granular lymphocyte expansion to happen in patients who have received a blood stem cell transplant (SCT) between 3 to 15 months after the SCT. In this research study, researchers want to find how well dasatinib can be tolerated, the best dose to take of dasatinib and how to estimate how often large granular lymphocytic cellular expansion happens at the best dose of dasatinib.
Interventions
- OTHER laboratory biomarker analysis
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-05 |
| Est. Completion | 2018-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01643603
The ClinicalTrials.gov registry entry for NCT01643603 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01643603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01643603 about?
NCT01643603 is a clinical study titled "Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies". This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells. Researchers think that dasatinib may cause large granular lymphocyte expans...
What is the current status of trial NCT01643603?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2012-05. Estimated completion is 2018-10-09.
What interventions are being tested in trial NCT01643603?
The interventions under investigation include: laboratory biomarker analysis (OTHER), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT01643603?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.